Kelleher Financial Advisors’s GSK GSK Stock Holding History

Kelleher Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.19K	Buy	118 +59	+100%	+$3.12K	﹤0.01%	655
2026 Q1	$3.26K	Hold	59	–	–	﹤0.01%	617
2025 Q4	$2.89K	Hold	59	–	–	﹤0.01%	646
2025 Q3	$2.55K	Buy	+59	New	+$2.31K	﹤0.01%	578
2025 Q1	–	Sell	-11,387	Closed	-$385K	–	134
2024 Q4	$385K	Buy	11,387 +1,357	+14%	+$48.9K	0.15%	82
2024 Q3	$410K	Buy	10,030 +96	+1%	+$3.93K	0.16%	81
2024 Q2	$382K	Hold	9,934	–	–	0.16%	84
2024 Q1	$426K	Hold	9,934	–	–	0.18%	78
2023 Q4	$368K	Sell	9,934 -904	-8%	-$32.5K	0.17%	73
2023 Q3	$393K	Buy	10,838 +105	+1%	+$3.73K	0.2%	69
2023 Q2	$383K	Buy	10,733 +57	+0.5%	+$2.04K	0.22%	75
2023 Q1	$380K	Buy	10,676 +41	+0.4%	+$1.43K	0.25%	73
2022 Q4	$374K	Buy	10,635 +21	+0.2%	+$699	0.28%	62
2022 Q3	$312K	Buy	+10,614	New	+$402K	0.22%	77

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Kelleher Financial Advisors's GSK Position: Q2 2026 in Review

Kelleher Financial Advisors increased its GSK (GSK) stake by 100% in Q2 2026, buying an estimated $3.12K and bringing the position to 118 shares worth $6.19K. The position accounts for ﹤0.01% of the portfolio, ranked #655.

Kelleher Financial Advisors first reported a position in GSK in Q3 2022 and has held it in 14 quarters since. The position peaked at $426K in Q1 2024. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Kelleher Financial Advisors held 118 shares of GSK worth $6.19K as of Q2 2026.
Kelleher Financial Advisors bought 59 GSK shares in Q2 2026, an estimated $3.12K.
GSK made up ﹤0.01% of Kelleher Financial Advisors's portfolio in Q2 2026, its #655 holding.
Kelleher Financial Advisors first reported a position in GSK in Q3 2022 and has held it in 14 quarters since.
Kelleher Financial Advisors's GSK position peaked at $426K in Q1 2024.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Kelleher Financial Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.